Lixisenatide: First global approval

Drugs

Volumn 73, Issue 4, 2013, Pages 383-391

  Elkinson, Shelley ^a   Keating, Gillian M ^b  

^a Adis R and D Insight   (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; LIXISENATIDE; METFORMIN; PIOGLITAZONE;

ARTICLE; BACKACHE; CYSTITIS; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG INFORMATION; DRUG SAFETY; DYSPEPSIA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INFLUENZA; INJECTION SITE PRURITUS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING;

ADULT; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON;

EID: 84878869094     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0033-3     Document Type: Article

References (44)

1. Christensen M, Knop FK, Holst JJ, et al. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Idrugs. 2009;12(8):503-13.
2. Werner U, Haschke G, Herling AW, et al. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164(2-3):58-64.
3. Thorkildsen C, Neve S, Larsen BD, et al. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther. 2003;307(2):490-6.
4. Gallwitz B. Glucagon-like peptide1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs. 2011;71(13):1675-88.
5. Sanofi. Once-daily Lyxumia® (lixisenatide) approved for treatment of type 2 diabetes in Europe. 2013. http://www.sanofi.com. Accessed 8 Feb 2013.
6. Sanofi. Sanofi New Drug Application for lixisenatide accepted for review by FDA. 2013. http://en.sanofi.com. Accessed 21 Feb 2013.
7. European Medicines Agency. Lyxumia (lixisenatide): EU summary of product characteristics. 2013. http://ec.europa.eu. Accessed 13 Feb 2013.
8. ® (insulin glargine) in type 2 diabetes. 2011. http://en.sanofi.com. Accessed 8 Feb 2013.
9. ® (lixisenatide). 2012. http://www.sanofi.com. Accessed 8 Feb 2013.
10. Christensen M, Knop FK, Vilsbøll T. The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. Expert Rev Endocrinol Metab. 2011;6(4):513-25.
11. Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35(6):1225-31.
12. Seino Y, Akane T, Niemoller E, et al. Long-term safety of once-daily (QD) lixisenatide in Japanese patients with type 2 diabetes (T2DM): GetGoal-Mono Japan [abstract no. PCS-30-5]. In: 9th International Diabetes Federation Western Pacific Region Congress and 4th Scientific Meeting of the Asian Association for the Study of Diabetes, Kyoto; 2012. p. 24-27.
13. Ratner RE, Hanefeld M, Shamanna P, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (GetGoal-S) [abstract no. 785]. Diabetologia. 2011;54(Suppl. 1):S317.
14. Pan CY, Zhao Q, Niemoeller E. Lixisenatide in Asian patients with type 2 diabetes (T2DM) uncontrolled on metformin ± sulfonylurea (SU): GetGoal-M Asia [abstract no. PCS-20-3]. 9th International Diabetes Federation Western Pacific Region Congress and 4th Scientific Meeting of the Asian Association for the Study of Diabetes, Kyoto; 24-27 Nov 2012.
15. Pinget M, Goldenberg R, Niemoeller E, et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P) [abstract no. 810]. Diabetologia. 2012;55(Suppl. 1):S334.
16. Riddle M, Home P, Marre M, et al. Efficacy and safety of once-daily lixisenatide in type 2 diabetes insufficiently controlled with basal insulin ± metformin: GetGoal-L study [abstract no. 983-P]. Diabetes. 2012;61(Suppl. 1):A251.
17. Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910-7.
18. Rosenstock J, Forst T, Aronson R, et al. Once-daily lixisenatide added on to consistently titrated insulin glargine plus oral agents in type 2 diabetes: the GetGoal-Duo 1 study [abstract no. 807]. Diabetologia. 2012;55(Suppl. 1):S333.
19. Ahren B, Dimas AL, Miossec P. Efficacy and safety of lixisenatide QD morning and evening injections vs placebo in T2DM inadequately controlled on metformin (GetGoal-M) [abstract no. O-0591]. In: 21st World Diabetes Congress, Dubai; 4-8 Dec 2011.
20. Bolli G, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1) [abstract no. 784]. Diabetologia. 2011;54(Suppl. 1):S316-7.
21. Rosenstock J, Raccah D, Korányi L, et al. Efficacy and safety of lixisenatide once-daily versus exenatide twice-daily in patients with type 2 diabetes insufficiently controlled on metformin (GetGoal-X) [abstract no. 786]. Diabetologia. 2011;54(Suppl. 1):S317-8.
22. Zealand P. Zealand Pharma announces that its partner Sanofi has applied for regulatory approval of lixisenatide (Lyxumia(R))1 for the treatment of type 2 diabetes in Japan. 2012. http://www.zealandpharma.com. Accessed 8 Feb 2013.
23. Sanofi aventis, Zealand Pharma AS. Phase III program for AVE0010/ZP10 licensed from Zealand Pharma A/S will begin in the first quarter of 2008. 2008. http://www.zp.com. Accessed 8 Feb 2013.
24. Zealand Pharma AS. Zealand Pharma announces an extension of the lixisenatide global licensing agreement with sanofi-aventis for type-2 diabetes. 2010. http://www.zealandpharma.com. Accessed 8 Feb 2013.
25. Aventis, Zealand Pharma AS. Aventis and Zealand Pharma sign licensing deal. 2003. http://www.aventis.com. Accessed 8 Feb 2013.
26. Sanofi. Combined general shareholder meeting of May 6, 2011. 2011. http://www.sanofi.com. Accessed 8 Feb 2013.
27. Becker RH, Kapitza C, Stechl J, et al. Restitution of glucose disposition with lixisenatide in subjects with type 2 diabetes [abstract no. 813]. Diabetologia. 2012;55(Suppl. 1):S335-6.
28. Distiller L, Ruus PE. Pharmacokinetics and pharmacodynamics of GLP-1 agonist AVE0010 in type 2 diabetes patients [abstract no. 520-P]. Diabetes. 2008;57(Suppl. 1):154-5.
29. Kapitza C, Forst T, Coester HV, et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab (Epub 2013 Jan 31).
30. Lorenz M, Pfeiffer C, Steinsträer A, et al. Effects of lixisenatide once daily on gastric emptying and its relationship to postprandial glycaemia in type 2 diabetes mellitus [abstract no. 808]. Diabetologia. 2012;55(Suppl. 1):S333-4.
31. Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther (Epub 2013 Feb 13).
32. Hübschle T, Schäfer H-L, Juretschke H-P, et al. Anti-atherosclerotic activity of lixisenatide in ApoE knockout mice [abstract no. 809]. Diabetologia. 2012;55(Suppl. 1):S334.
33. Ruetten H, Huber J, Meister S, et al. Protective effects of the GLP-1 receptor agonist lixisenatide on ischaemia-reperfusion-induced myocardial infarction in an isolated rat heart model [abstract no. 810]. Diabetologia. 2011;54(Suppl. 1):S329.
34. Wohlfart P, Linz W, Linz D, et al. Cardioprotective effect of chronic treatment with lixisenatide in an in vivo rat model of myocardial ischaemia/reperfusion-induced injury [abstract no. 811]. Diabetologia. 2012;55(Suppl. 1):S335.
35. Liu Y-H, Ruus P. Effect of the GLP-1 receptor agonist AVE0010 on the absorption of concomitant oral drugs: acetaminophen and ethinylestradiol/ levonorgestrel [abstract no. 776]. In: 45th Annual Meeting of the European Association for the Study of Diabetes, Austria; 29 Sep-2 Oct 2009.
36. Liu YH, Ruus P, Steinstraesser A, et al. Effect of the GLP-1 agonist lixisenatide on the pharmacokinetics of warfarin [abstract no. 2128-PO]. In: 70th Annual Scientific Sessions of the American Diabetes Association, Orlando (FL); 25-29 Jun 2010.
37. Dahmen R, Steinstraesser A, Poitiers F, et al. Interaction of subcutaneous lixisenatide 20 μg QD on pharmacokinetic and pharmacodynamic properties of oral ramipril 5 mg QD [abstract]. In: 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest; 26-29 Jun 2011.
38. Ratner RE, Rosenstock J, Boka G, et al. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2010;27(9):1024-32.
39. Sanofi. Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (lixisenatide) (ELIXA) [ClinicalTrials.gov identifier NCT01147250]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. Accessed 19 Feb 2013.
40. Sanofi. Efficacy and safety of lixisenatide versus insulin glulisine on top of insulin glargine with or without metformin in type 2 diabetic patients (GetGoal-Duo 2) [ClinicalTrials.gov identifier NCT01768559]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. Accessed 5 Mar 2013.
41. Sanofi. Comparison of lixisenatide injected prior to the main meal of the day versus prior to breakfast in type 2 diabetic patients on metformin [ClinicalTrials.gov identifier NCT01517412]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. Accessed 19 Feb 2013.
42. Sanofi. Assessment of the efficacy and safety of lixisenatide in patients with type 2 diabetes insufficiently controlled with basal insulin +/- metformin [ClinicalTrials.gov identifier NCT01632163]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. Accessed 19 Feb 2013.
43. Sanofi. Pharmacodynamic effects of lixisenatide compared to liraglutide in patients with type 2 diabetes not adequately controlled with insulin glargine with or without metformin [ClinicalTrials.gov identifier NCT01596504]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. Accessed 19 Feb 2013.
44. Sanofi. Evaluation of the blood levels of the drug (lixisenatide), the plasma glucose levels and safety in paediatric and adult patients with type 2 diabetes [ClinicalTrials.gov identifier NCT01572649]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. Accessed 20 Feb 2013.